Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
CH0013841017
Thu, 16.02.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Expansion
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
16.02.2023 / 14:00 CET/CEST
Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates
The Visp (CH) investment includes two manufacturin [ … ]
Thu, 16.02.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Expansion
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
16.02.2023 / 14:00 CET/CEST
Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates
The Visp (CH) investment includes two manufacturin [ … ]
Wed, 08.02.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Bond/Financing
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
08.02.2023 / 18:30 CET/CEST
Basel, Switzerland, 08 February 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 300 million straight-bond issu [ … ]
Wed, 08.02.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Bond/Financing
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
08.02.2023 / 18:30 CET/CEST
Basel, Switzerland, 08 February 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 300 million straight-bond issu [ … ]
Tue, 01.11.2022
Lonza Group AG
Lonza Group AG
/ Key word(s): Product Launch
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
01.11.2022 / 07:00 CET/CEST
Lonza meets pressing market need by launching first ever coating-free capsule to support intestinal delivery of acid-sensitive APIs
Innovative Capsugel® [ … ]
Tue, 01.11.2022
Lonza Group AG
Lonza Group AG
/ Key word(s): Product Launch
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
01.11.2022 / 07:00 CET/CEST
Lonza meets pressing market need by launching first ever coating-free capsule to support intestinal delivery of acid-sensitive APIs
Innovative Capsugel® [ … ]
Mon, 12.09.2022
Lonza Group AG
Lonza Group AG
/ Key word(s): Personnel
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
12.09.2022 / 07:00 CET/CEST
Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee
Daniel will commence his tenure with Lonza Group on 1 November 2022, bringi [ … ]
Mon, 12.09.2022
Lonza Group AG
Lonza Group AG
/ Key word(s): Personnel
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
12.09.2022 / 07:00 CET/CEST
Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee
Daniel will commence his tenure with Lonza Group on 1 November 2022, bringi [ … ]
Tue, 06.09.2022
Lonza Group AG
Lonza Group AG
/ Key word(s): Partnership
Lonza and Touchlight collaborate on end-to-end mRNA offering
06.09.2022 / 07:00 CET/CEST
Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM)
Touchlight provides synthetic [ … ]
Tue, 06.09.2022
Lonza Group AG
Lonza Group AG
/ Key word(s): Partnership
Lonza and Touchlight collaborate on end-to-end mRNA offering
06.09.2022 / 07:00 CET/CEST
Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM)
Touchlight provides synthetic [ … ]